Guanfacine

Common brands: Intuniv, Guanfacine Hydrochloride, Guanfacine Extended-Release, Abilify, Risperdal

Top reporter: Takeda Pharmaceuticals America, Inc.

Central alpha-2 Adrenergic Agonist [EPC]Atypical Antipsychotic [EPC]Central Nervous System Stimulant [EPC]Benzodiazepine [EPC]Anti-epileptic Agent [EPC]
7,600
Total Reports
3,133
Serious Reports
242
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (3.18%)

Patient Demographics

Male
3,902
Female
2,291

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Guanfacine.

# Reaction Reports % of Total
1 DRUG INEFFECTIVE 797
9.9%
2 OFF LABEL USE 616
7.6%
3 SOMNOLENCE 458
5.7%
4 AGGRESSION 379
4.7%
5 FATIGUE 337
4.2%
6 HYPOTENSION 292
3.6%
7 DIZZINESS 283
3.5%
8 HEADACHE 272
3.4%
9 INSOMNIA 270
3.3%
10 BRADYCARDIA 267
3.3%
11 SUICIDAL IDEATION 267
3.3%
12 ANXIETY 256
3.2%
13 NAUSEA 251
3.1%
14 INTENTIONAL OVERDOSE 233
2.9%
15 ELECTROCARDIOGRAM QT PROLONGED 232
2.9%
16 VOMITING 226
2.8%
17 ABNORMAL BEHAVIOUR 218
2.7%
18 TOXICITY TO VARIOUS AGENTS 217
2.7%
19 NO ADVERSE EVENT 208
2.6%
20 PRODUCT QUALITY ISSUE 206
2.5%
21 AGITATION 199
2.5%
22 WEIGHT INCREASED 198
2.4%
23 CONDITION AGGRAVATED 187
2.3%
24 DECREASED APPETITE 181
2.2%
25 PRODUCT USE ISSUE 178
2.2%
26 DRUG INTERACTION 176
2.2%
27 PRODUCT SUBSTITUTION ISSUE 174
2.2%
28 DEPRESSION 172
2.1%
29 SYNCOPE 171
2.1%
30 IRRITABILITY 166
2.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.